Drugs that contain Dihydroergotamine Mesylate
1. Trudhesa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550036 | IMPEL PHARMS | Nasal drug delivery device |
Sep, 2032
(8 years from now) | |
| US10507295 | IMPEL PHARMS | Nasal drug delivery device |
Dec, 2032
(8 years from now) | |
| US10940278 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Jan, 2033
(8 years from now) | |
| US9919117 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Mar, 2033
(8 years from now) | |
| US11266799 | IMPEL PHARMS | In-line nasal delivery device |
Nov, 2036
(12 years from now) | |
| US11185497 | IMPEL PHARMS | Intranasal delivery of dihydroergotamine by precision olfactory device |
Jan, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 02, 2024 |
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
TRUDHESA family patents
